Cardurion Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$260M
- Investors
-
16
Cardurion General Information
Description
Developer of cardiovascular therapeutics intended to treat cardiovascular diseases. The company's therapeutics offer advanced novel mechanisms to develop new treatments for heart diseases causing morbidity and mortality, enabling healthcare professionals to prevent arrhythmia disorders and heart failures.
Contact Information
Website
www.cardurion.comCorporate Office
- 78 Blanchard Road
- Suite 200
- Burlington, MA 01803
- United States
Corporate Office
- 78 Blanchard Road
- Suite 200
- Burlington, MA 01803
- United States
Cardurion Timeline
Cardurion Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | 10-Jul-2024 | $260M | Completed | Pre-Clinical Trials | ||
| 3. Later Stage VC (Series A) | 12-Jul-2023 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC (Series A1) | 30-Dec-2022 | $46.1M | $61.8M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 04-Apr-2017 | $15.7M | $15.7M | Completed | Startup |
Cardurion Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-5 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 5,198,934 | $0.000100 | 6% | $2.78 | $2.78 | 1x | $2.78 | 3.35% |
| Series A-1 | 14,101,191 | $0.000100 | 6% | $3.27 | $3.27 | 1x | $3.27 | 9.09% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Cardurion Comparisons
Industry
Financing
Details
Cardurion Competitors (40)
One of Cardurion’s 40 competitors is Iconic Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Iconic Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| InCarda Therapeutics | Venture Capital-Backed | Newark, CA | ||||
| Amyndas Pharmaceuticals | Accelerator/Incubator Backed | Bala Cynwyd, PA | ||||
| Cytokinetics | Formerly VC-backed | South San Francisco, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Cardurion Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cardurion Patents
Cardurion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250145630-A1 | Polymorphs of a pyridinylimidazo[1,2-b]pyridazine | Pending | 07-Nov-2023 | ||
| AU-2021370658-A1 | Pde9 inhibitors for treating cardiac failure | Pending | 27-Oct-2020 | ||
| EP-4236951-A1 | Pde9 inhibitors for treating cardiac failure | Pending | 27-Oct-2020 | ||
| CA-3199766-A1 | Pde9 inhibitors for treating cardiac failure | Pending | 27-Oct-2020 | ||
| JP-2023550269-A | Pde9 inhibitors to treat heart failure | Pending | 27-Oct-2020 | A61K31/4985 |
Cardurion Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cardurion Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ascenta Capital | Venture Capital | Minority | ||
| Blue Owl Capital | Asset Manager | Minority | ||
| Delos Capital Partners | Venture Capital | Minority | ||
| Digitalis Ventures | Venture Capital | Minority | ||
| Farallon Capital Management | Hedge Fund | Minority |
Cardurion Investments (1)
Cardurion’s most recent deal was a Corporate Asset Purchase with Imara (Phosphodiesterase, Tovinontrine and Other Assets of PDE9 Program) for . The deal was made on 10-Nov-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Imara (Phosphodiesterase, Tovinontrine and Other Assets of PDE9 Program) | 10-Nov-2022 | Corporate Asset Purchase | Buildings and Property |
Cardurion FAQs
-
When was Cardurion founded?
Cardurion was founded in 2017.
-
Where is Cardurion headquartered?
Cardurion is headquartered in Burlington, MA.
-
What is the size of Cardurion?
Cardurion has 50 total employees.
-
What industry is Cardurion in?
Cardurion’s primary industry is Biotechnology.
-
Is Cardurion a private or public company?
Cardurion is a Private company.
-
What is the current valuation of Cardurion?
The current valuation of Cardurion is .
-
What is Cardurion’s current revenue?
The current revenue for Cardurion is .
-
How much funding has Cardurion raised over time?
Cardurion has raised $622M.
-
Who are Cardurion’s investors?
Ascenta Capital, Blue Owl Capital, Delos Capital Partners, Digitalis Ventures, and Farallon Capital Management are 5 of 16 investors who have invested in Cardurion.
-
Who are Cardurion’s competitors?
Iconic Therapeutics, InCarda Therapeutics, Amyndas Pharmaceuticals, Cytokinetics, and Alnylam Pharmaceuticals are some of the 40 competitors of Cardurion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
